KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Globus Medical (GMED) EBITDA Margin (2016 - 2025)

Globus Medical (GMED) has disclosed EBITDA Margin for 15 consecutive years, with 17.55% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin rose 1350.0% year-over-year to 17.55%, compared with a TTM value of 19.06% through Dec 2025, up 1484.0%, and an annual FY2025 reading of 19.06%, up 1484.0% over the prior year.
  • EBITDA Margin was 17.55% for Q4 2025 at Globus Medical, up from 15.56% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 28.88% in Q2 2025 and bottomed at 1.31% in Q1 2024.
  • Average EBITDA Margin over 5 years is 13.05%, with a median of 15.76% recorded in 2022.
  • The sharpest move saw EBITDA Margin skyrocketed 2556bps in 2021, then crashed -2095bps in 2024.
  • Year by year, EBITDA Margin stood at 4.55% in 2021, then skyrocketed by 361bps to 21.01% in 2022, then crashed by -82bps to 3.82% in 2023, then grew by 6bps to 4.05% in 2024, then soared by 333bps to 17.55% in 2025.
  • Business Quant data shows EBITDA Margin for GMED at 17.55% in Q4 2025, 15.56% in Q3 2025, and 28.88% in Q2 2025.